Novartis AG shares slumped after the drugmaker reported earnings that came short of analysts’ estimates on weak revenue from Pluvicto, a prostate cancer treatment that faced supply constraints.
SMALL CAPS IDEA: Destiny Pharma is playing its part in the race to diffuse a deadly $1trillion healthcare timebomb with two phase III-ready preventative medicines.
It s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent after drug giant AstraZeneca delivered an $11million post-Christmas windfall.